La presentazione è in caricamento. Aspetta per favore

La presentazione è in caricamento. Aspetta per favore

Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study by Sara Bringhen, Maria.

Presentazioni simili


Presentazione sul tema: "Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study by Sara Bringhen, Maria."— Transcript della presentazione:

1 Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study by Sara Bringhen, Maria Teresa Petrucci, Alessandra Larocca, Concetta Conticello, Davide Rossi, Valeria Magarotto, Pellegrino Musto, Luana Boccadifuoco, Massimo Offidani, Paola Omedé, Fabiana Gentilini, Giovannino Ciccone, Giulia Benevolo, Mariella Genuardi, Vittorio Montefusco, Stefania Oliva, Tommaso Caravita, Paola Tacchetti, Mario Boccadoro, Pieter Sonneveld, and Antonio Palumbo Blood Volume 124(1):63-69 July 3, 2014 ©2014 by American Society of Hematology

2 Kaplan-Meier analysis of time to response, showing proportion of responding patients achieving their best response over time. Kaplan-Meier analysis of time to response, showing proportion of responding patients achieving their best response over time. Sara Bringhen et al. Blood 2014;124:63-69 ©2014 by American Society of Hematology

3 Kaplan-Meier analysis of time to events data.
Kaplan-Meier analysis of time to events data. (A) PFS. (B) OS. Sara Bringhen et al. Blood 2014;124:63-69 ©2014 by American Society of Hematology


Scaricare ppt "Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study by Sara Bringhen, Maria."

Presentazioni simili


Annunci Google